BioLineRx Ltd.
Long
Aktualisiert

BLRX-BREAKOUT-UPDATE

389
BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

Snapshot

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB






Anmerkung
As expected, a very strong rally today!
Anmerkung
Snapshot
Anmerkung
We got a big runway...
Anmerkung
Reminder this is a WEEKLY chart...

Meaning this move is far from over...
Anmerkung
Snapshot
Anmerkung
Buckle up!
Anmerkung
Snapshot
Anmerkung
Target $2.24 (Sell Half)

Trade Price: 1.049
Anmerkung
Snapshot
Anmerkung
Snapshot
Anmerkung
Bull Flag
Anmerkung
BLRX will rally again tomorrow.
Anmerkung
Snapshot
Anmerkung
BLRX is about to rally again...
Anmerkung
BLRX continued to consolidate today.

Staying the course...
Anmerkung
Snapshot
Anmerkung
Snapshot
Anmerkung
Near-Term Target: $2.13
Anmerkung
Snapshot
Anmerkung
Primary Wave 1 Complete
Anmerkung
Snapshot
Anmerkung
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
Anmerkung
Snapshot
Anmerkung
Snapshot
Anmerkung
Breakout Imminent
Anmerkung
Snapshot

Haftungsausschluss

Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.